(2E)-3-(4-fluorophenyl)-1-(4-nitrophenyl)prop-2-en-1-one | 102692-39-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: (2E)-3-(4-fluorophenyl)-1-(4-nitrophenyl)prop-2-en-1-one
• 英文别名: (E)-3-(4-fluorphenyl)-1-(4-nitrophenyl)prop-2-en-1-one；4-fluoro-4'-nitro-trans-chalcone；4-Fluor-4'-nitro-trans-chalkon；4-Fluoro-4'-nitrochalcone；(E)-3-(4-fluorophenyl)-1-(4-nitrophenyl)prop-2-en-1-one
• CAS: 102692-39-7
• 化学式: C₁₅H₁₀FNO₃
• 分子量: 271.248
• InChiKey: YMQIOFDMELMTTG-XCVCLJGOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  62.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2E)-3-(4-fluorophenyl)-1-(4-nitrophenyl)prop-2-en-1-one 、 (1E,6E)-1,7-bis(4-methoxyphenyl)hepta-1,6-diene-3,5-dione 在 caesium carbonate 作用下， 以 乙腈 为溶剂， 以84%的产率得到
  参考文献：
  名称：

  Conjugate addition of curcumins to chalcones and azodicarboxylates

  摘要：

  Cascade double Michael reaction of curcumins with chalcones in the presence of Cs2CO3 in CH3CN provided highly functionalized cyclohexanones in moderate to good yields (35-77%) and good to excellent diastereoselectivities (81:19 to 95:05). Similar reaction of curcumins with azodicarboxylates in the presence of DMAP in CH3CN stopped at the single Michael addition stage affording novel hydrazinodicarboxylates of curcumins in good to excellent yields (65-85%). (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2013.04.083
• 作为产物：
  描述：

  (E)-(4-fluorostyryl)trimethylsilane 在 sodium hydride 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 8.0h， 生成 (2E)-3-(4-fluorophenyl)-1-(4-nitrophenyl)prop-2-en-1-one
  参考文献：
  名称：

  Novel acylation of a vinyl group by the reaction of an aldehyde and a vinylselenonium ylide

  摘要：

  由(Z)-乙烯基硒鎓盐与氢化钠或氢化钾等碱反应生成的乙烯基硒鎓亚甲基，与芳香醛反应生成α，β-不饱和酮。

  DOI：

  10.1039/b100660f

文献信息

• Chalcone‐Supported Cardiac Mesoderm Induction in Human Pluripotent Stem Cells for Heart Muscle Engineering
  作者：Farah S. Raad、Taukeer A. Khan、Tilman U. Esser、James E. Hudson、Bhakti Irene Seth、Buntaro Fujita、Ravi Gandamala、Lutz F. Tietze、Wolfram-Hubertus Zimmermann

  DOI：10.1002/cmdc.202100222

  日期：2021.11.5

  Have a little heart: A screen for mesoderm inducing chalcones in human pluripotent stem cell cultures identified 4’-hydroxychalcone (4’HC) as an effective replacement for bone-morphogenetic protein 4 (BMP4) in supporting the derivation of engineered heart muscle (EHM)-formation competent cardiomyocytes.

  有点心：在人类多能干细胞培养物中筛选中胚层诱导查尔酮，发现 4'-羟基查尔酮 (4'HC) 可以有效替代骨形态发生蛋白 4 (BMP4)，支持工程化心肌 (EHM) 的衍生)-形成能力心肌细胞。
• Synthetic Chalcone Derivatives as Inhibitors of Cathepsins K and B, and Their Cytotoxic Evaluation
  作者：Suelem Demuner Ramalho、Aline Bernades、Giulio Demetrius、Caridad Noda-Perez、Paulo Cezar Vieira、Caio Yu dos Santos、James Almada da Silva、Manoel Odorico de Moraes、Kristiana Cerqueira Mousinho

  DOI：10.1002/cbdv.201200344

  日期：2013.11

  (15) showed significant cytotoxicities. The most effective compound was 15, which showed high cytotoxic activity with an IC50 value lower than 1 μg/ml, and no selectivity on the tumor cells evaluated. Substituents at C(4) of ring B were found to be essential for cytotoxicity. In addition, it was also demonstrated that some of these chalcones are moderate inhibitors of cathepsin K and have no activity

  通过 ClaisenSchmidt 缩合制备了一系列查耳酮衍生物 1-15，并评估了它们对肿瘤细胞系以及对蛋白水解酶（如组织蛋白酶 B 和 K）的细胞毒性。合成的化合物中，(E)-3-( 3,4-二甲氧基苯基)-1-苯基丙-2-en-1-one (12), (E)-3-(4-氯苯基)-1-苯基丙-2-en-1-one (13), ( E)-3-(4-甲氧基苯基)-1-苯基丙-2-en-1-one (14)和(E)-3-(4-硝基苯基)-1-苯基丙-2-en-1-one (15) 显示出显着的细胞毒性。最有效的化合物是 15，它显示出高细胞毒活性，IC50 值低于 1 μg/ml，并且对评估的肿瘤细胞没有选择性。发现环 B 的 C(4) 处的取代基对细胞毒性至关重要。此外，
• A New Lewis Acid System Palladium/TMSCl for Catalytic Aldol Condensation of Aldehydes with Ketones
  作者：Yulin Zhu、Yuanjiang Pan

  DOI：10.1246/cl.2004.668

  日期：2004.6

  catalyzed the aldol condensation reactions of different ketones with aldehydes in the presence of trimethylsilyl chloride (TMSCI). The following reactions were investigated: (1) aromatic aldehydes with cycloalkanones, (2) aromatic aldehydes with aromatic ketones, (3) cycloalkanones with aliphatic aldehydes, and (4) the self-condensation reactions of aliphatic aldehydes and cycloalkanones.

  在三甲基氯硅烷 (TMSCI) 存在下，钯炭有效地催化了不同酮与醛的羟醛缩合反应。研究了以下反应：（1）芳香醛与环烷酮，（2）芳香醛与芳香酮，（3）环烷酮与脂肪醛，以及（4）脂肪醛和环烷酮的自缩合反应。
• Structural and femtosecond third-order nonlinear optical properties of electron donor – acceptor substituted chalcones: An experimental and computational approach
  作者：Parutagouda Shankaragouda Patil、Neelamma B. Gummagol、Anusha Ekbote、Qin Ai Wong、Ching Kheng Quah、Mohd Shkir、Shivaraj R. Maidur、S. Venugopal Rao

  DOI：10.1016/j.molstruc.2020.128523

  日期：2020.11

  wavelength and optical band gaps of the chalcones were evaluated. The thermal stability and the melting point of the chalcones were determined from the TGA/DTA techniques. The ultrafast third-order NLO properties of the three chalcones in solution (0.01 M) were evaluated by Z-scan technique using femtosecond (fs) pulses from Ti: Sapphire laser (∼150 fs, 80 MHz, 800 nm). Third-order nonlinear absorption

  摘要 两个 D-π-A-π-A [ (2E)-3-(3-氯苯基)-1-(3-硝基苯基)prop-2-en-1 的结构和三阶非线性光学 (NLO) 性质-一个 (3C3NC) 和 (2E)-3-(4-氟苯基)-1-(4-硝基苯基)prop-2-en-1-one (FNC)] 和一个 D-π-A-π-D [ (2E)-1-(9-蒽基)-3-(4-氟苯基) prop-2-en-1-one (FANC)] 型查尔酮衍生物进行了实验和理论研究。所有三个查耳酮都是中心对称的 (CS) 并在 P21/c 空间群中结晶。在晶体堆积中，所有化合物都表现出C-H⋯O氢键和π···π相互作用。根据 UV-Vis-NIR 吸收光谱，评估了查耳酮的截止波长和光学带隙。查耳酮的热稳定性和熔点由 TGA/DTA 技术确定。三种查耳酮在溶液 (0.01 M) 中的超快三阶 NLO 特性通过 Z 扫描技术使用 Ti: 蓝宝石激光器
• SUBSTITUTED-PHENYL KETONE DERIVATIVES AS IP ANTAGONISTS
  申请人：——

  公开号：US20020091147A1

  公开（公告）日：2002-07-11

  This invention relates to compounds which are generally IP receptor modulators, particularly IP receptor antagonists, and which are represented by Formula I: 1 wherein A, R 1 and R 2 are as defined in the specification; and individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds and methods for their use as therapeutic agents.

  本发明涉及一些化合物，通常是IP受体调节剂，特别是IP受体拮抗剂，其由公式I表示：其中A，R1和R2如说明书中所定义的那样；以及其各个异构体，外消旋或非外消旋异构体混合物和药学上可接受的盐或溶剂。本发明还涉及含有这样的化合物的制药组合物以及其作为治疗剂的使用方法。